Author(s): Belcaro G, Cesarone MR, Dugall M, Hosoi M, Ippolito E
Aim. In this study we investigated benefits of a Pycnogenol –coenzyme Q10 combination (PycnoQ10) taken as an adjunct tomedical treatment in stable heart failure patients. The aim of this single-blinded,12-week observational study was to provi-de functional parameters such as exercise capacity,ejectionfraction and distal edema.
Methods. The essential element for inclusion was a stable level of heart failure within the past three months and stable NYHA classII or III (6 months). The heart failure management was in accor-dance with AHA guidelines for “best treatment.”The treatmentand control groups were comparable at baseline. The mean ageof the PycnoQ10-treated patients was 61.3±7.1 years and 62.1±3.7in the control group. All patients were taking medication andmost patients (>75%) used three or more drugs for heart failu-re treatment. There were two dropouts in the PycnoQ10 treatmentgroup and 6 in the control group (5 NYHA III patients).
Results. Nine PycnoQ10 treated patients (out of 32) and 3 (outof 21) taking placebo improved NYHA class. Systolic and dia-stolic pressure as well as heart rate and respiratory rate weresignificantly lowered with PycnoQ10 as compared to the con-trol group (P<0.05). No significant changes were observed incontrols. Heart ejection fraction increased by 22.4% in thetreatment group (P<0.05) versus 4.0% in controls. Walkingdistance on treadmill increased 3.3-fold in PycnoQ10 treatedpatients (P<0.05) but marginally improved in the control group.Distal edema decreased significantly in PycnoQ10 treatedpatients and only slightly in controls.
Conclusion. The association of Pycnogenol and CoQ10 may offeran important therapeutic option with a very good tolerability thatimproves heart failure management without side effects